{"classes":[{"categories":[{"measurements":[{"comment":"Median DOR and DOR upper limit not reached: No progressive disease by the time of last disease assessment.","groupId":"OG000","lowerLimit":"3","upperLimit":"NA","value":"NA"},{"comment":"Median DOR and DOR upper limit not reached: No progressive disease by the time of last disease assessment.","groupId":"OG001","lowerLimit":"9","upperLimit":"NA","value":"NA"},{"comment":"DOR upper limit not reached: No progressive disease by the time of last disease assessment.","groupId":"OG002","lowerLimit":"9","upperLimit":"NA","value":"35"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"12"}],"units":"Participants"}],"title":"Strongly PD-L1 Positive"},{"categories":[{"measurements":[{"comment":"Median DOR and DOR upper limit not reached: No progressive disease by the time of last disease assessment.","groupId":"OG000","lowerLimit":"3","upperLimit":"NA","value":"NA"},{"comment":"Median DOR and DOR upper limit not reached: No progressive disease by the time of last disease assessment.","groupId":"OG001","lowerLimit":"9","upperLimit":"NA","value":"NA"},{"comment":"DOR upper limit not reached: No progressive disease by the time of last disease assessment.","groupId":"OG002","lowerLimit":"6","upperLimit":"NA","value":"27"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"32"}],"units":"Participants"}],"title":"All PD-L1 Positive"}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"32"}],"units":"Participants"}],"description":"DOR is measured from the time measurement criteria were first met for CR/PR (whichever was first recorded) until the first date that death or progressive disease was objectively documented (taking as reference for progressive disease the smallest measurements recorded on study). Non-responders were not included in the analysis. DOR was analyzed using the Kaplan-Meier method and is reported in weeks. Per protocol, final analysis for this secondary outcome measure was performed for the first pembrolizumab course and docetaxel treatment arms, with a protocol-specified analysis data cutoff date of 30 Sep 2015.","dispersionType":"Full Range","groups":[{"description":"Participants received pembrolizumab 2 mg/kg IV over 30 minutes Q3W for up to 2 years. Qualified participants who received the first course of pembrolizumab 2 mg/kg Q3W for up to 2 years, but experienced disease progression, initiated a second course of pembrolizumab at the investigator's discretion, at 200 mg IV Q3W for up to 1 year.","id":"OG000","title":"Pembrolizumab 2 mg/kg"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years. Qualified participants who received the first course of pembrolizumab 10 mg/kg Q3W for up to 2 years, but experienced disease progression, initiated a second course of pembrolizumab at the investigator's discretion, at 200 mg IV Q3W for up to 1 year.","id":"OG001","title":"Pembrolizumab 10 mg/kg"},{"description":"Participants received docetaxel 75 mg/m\\^2 IV over 1 hour Q3W for up to 2 years. Qualified participants who received docetaxel 75 mg/m\\^2 Q3W for up to 2 years, but experienced disease progression, switched over to pembrolizumab, at the investigator's discretion, at 200 mg IV Q3W for up to 2 years.","id":"OG002","title":"Docetaxel 75 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"Per protocol, DOR for the first pembrolizumab course and docetaxel treatment arms was analyzed in all randomized participants who demonstrated a CR/PR and had strongly PD-L1 positive and all PD-L1 positive DOR data available and usable. Participants were included in the treatment group to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)","title":"Duration of Response (DOR) by RECIST 1.1","type":"SECONDARY","unitOfMeasure":"Weeks"}